Delving into the Latest Updates on Human cord derived MSC cell (Help Therapeutics ) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

hMSC100

Target-

Action-

Mechanism

Stem cell replacements

Therapeutic Areas

Endocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases

Active Indication

Osteoporosis, Postmenopausal

Inactive Indication-

Originator Organization

Aipu Regenerative Medicine Technology (Shenzhen) Co., Ltd.

Active Organization

Aipu Regenerative Medicine Technology (Shenzhen) Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：考察注射用人脐带间充质干细胞（hMSC100）在极高骨折风险的绝经后妇女骨质疏松症患者中的安全性及耐受性，为后续临床试验设计提供依据。次要目的：探索注射用人脐带间充质干细胞（hMSC100）在极高骨折风险的绝经后妇女骨质疏松症患者中的药代动力学特征及初步有效性。

[Translation]

Main purpose: To investigate the safety and tolerability of human umbilical cord mesenchymal stem cells (hMSC100) for injection in postmenopausal women with osteoporosis at very high risk of fracture, and to provide a basis for the design of subsequent clinical trials. Secondary purpose: To explore the pharmacokinetic characteristics and preliminary effectiveness of human umbilical cord mesenchymal stem cells (hMSC100) for injection in postmenopausal women with osteoporosis at very high risk of fracture.

Start Date-

Sponsor / Collaborator

Aipu Regenerative Medicine Technology (Shenzhen) Co., Ltd.

100 Clinical Results associated with Human cord derived MSC cell (Help Therapeutics )

Login to view more data

100 Translational Medicine associated with Human cord derived MSC cell (Help Therapeutics )

Login to view more data

100 Patents (Medical) associated with Human cord derived MSC cell (Help Therapeutics )

Login to view more data

100 Deals associated with Human cord derived MSC cell (Help Therapeutics )

Login to view more data